Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pink Sheet Podcast: Insys Divests Opioids, Pretomanid's Advisory Committee Meeting, And Biosimilar User Fee Collections

Executive Summary

Our discussion of the Insys corporate integrity agreement and bankruptcy filling, US FDA's advisory committee meeting on the TB treatment pretomanid, and new data showing lower US biosimilar user fee collections than expected.

You may also be interested in...



Market For COVID-19 Therapeutics Will Exceed Government Demand, US Believes

HHS Secretary Azar says $1bn of the $2.5bn emergency supplemental funding request is for vaccine development.

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 

US FDA Tech Modernization Plan’s Costs Uncertain

Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.

Topics

Related Companies

UsernamePublicRestriction

Register

PS125468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel